Provided by Tiger Fintech (Singapore) Pte. Ltd.

ImmunityBio, Inc.

2.57
+0.16006.64%
Pre-market: 2.55-0.0200-0.78%06:42 EDT
Volume:21.62M
Turnover:52.85M
Market Cap:2.43B
PE:-5.25
High:2.61
Open:2.42
Low:2.35
Close:2.41
52wk High:7.48
52wk Low:1.83
Shares:945.25M
Float Shares:194.00M
Volume Ratio:2.77
T/O Rate:11.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4893
EPS(LYR):-0.5931
ROE:78.05%
ROA:-42.14%
PB:-4.26
PE(LYR):-4.33

Loading ...

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Sep 08

BRIEF-ImmunityBio’s ANKTIVA® Improves Survival in Advanced NSCLC by Reversing Lymphopenia

Reuters
·
Sep 08

ImmunityBio Announces Breakthrough Findings: ANKTIVA® Reverses Lymphopenia and Extends Survival in Advanced Lung Cancer Patients

Reuters
·
Sep 08

Immunitybio’s Anktiva® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy

THOMSON REUTERS
·
Sep 08

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Aug 27

BUZZ-U.S. STOCKS ON THE MOVE-Trump Media, Gold miners, Cracker Barrel

Reuters
·
Aug 26

BUZZ-ImmunityBio on positive early data for cancer treatment regimen

Reuters
·
Aug 26

BRIEF-Initial Data Shows 100% Disease Control in 5 of 5 Patients With Recurrent Glioblastoma Treated With ImmunityBio’s ANKTIVA, NK Cell Therapy Plus Optune Gio Device

Reuters
·
Aug 26

Immunitybio Shares up 4.9% Premarket After Initial Data From Co's Experimental Cancer Treatment Shows Promise

THOMSON REUTERS
·
Aug 26

Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With Immunitybio’s Anktiva®, Nk Cell Therapy Plus Optune Gio® Device

THOMSON REUTERS
·
Aug 26

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Aug 19

ImmunityBio Inc. Launches Phase 2 Clinical Study of ANKTIVA® to Address Long COVID Symptoms

Reuters
·
Aug 19

Immunitybio Announces Phase 2 Study of Anktiva® in Patients With Long Covid

THOMSON REUTERS
·
Aug 19

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Aug 14

BUZZ-U.S. STOCKS ON THE MOVE-Lumentum Holdings, ImmunityBio, V2X

Reuters
·
Aug 13

BUZZ-ImmunityBio rises after early data for blood cancer cell therapy

Reuters
·
Aug 13

ImmunityBio Announces Promising Results in Clinical Trial for CD19 CAR-NK Therapy in Non-Hodgkin Waldenstrom Lymphoma Patients

Reuters
·
Aug 13

Immunitybio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients With Chemotherapy-Free, First-in-Class Cd19 Car-Nk Immunotherapy

THOMSON REUTERS
·
Aug 13

Immunitybio Inc - Second Patient Maintains Complete Response at Six Months

THOMSON REUTERS
·
Aug 13

Stock Track | ImmunityBio Soars 5.12% as VA Hospital Begins Administering Anktiva® for Bladder Cancer

Stock Track
·
Aug 11